Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study

Table 3 Change in clinical status before and after switching

	Before switching		After switching
	OLZ-RIS (n=162)	RIS-OLZ (n=136)	OLZ-RIS (n=162)	RIS-OLZ (n=136)
Change in CGI-overall score from baseline ^a (Mean ± SD)	−0.75±1.05	−0.71±1.20	−1.15±1.12	−1.46±1.29
EPS ^b (%)	15.2	28.4	15.2	9.0
Loss of libido ^b (%)	28.8	37.8	31.3	26.7
Impotence/sexual dysfunction ^b (%)	18.9	29.3	22.0	19.6
Amenorrhoea/galactorrhea ^a (%)	12.0	12.6	17.7	5.9
Change in weight (kg) from baseline ^c (Mean ± SD)	3.14±6.05	1.43±4.21	4.11±8.39	1.95±8.90

^aThe difference between before and after switching was significant in both groups (p<0.05).
^bThe difference between before and after switching was significant only in patients who switched to olanzapine (i.e., the RIS-OLZ group).
^cThe difference between before and after switching was not significant in either group.
OLZ-RIS: Patients who switched from olanzapine to risperidone.
RIS-OLZ: Patients who switched from risperidone to olanzapine.
EPS: Extrapyramidal Symptom.

ISSN: 1471-244X